Please login to read the full article.
Scrip Regulatory Affairs
New pharmacovigilance rules in the EU and their impact on biosimilars and automatic substitution
10 November 2011
Burkhard Sträter
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EU court opinion on Losec case a blow for originator firms
- EU medtech regulators' group sticks to legally correct labelling decision, launches transparency initiative
- French govt promises "culture shock" in drug regulation, while price cuts and levies loom
- US drug, biologics chiefs give insight into biosimilar pathway planning efforts
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
